S&P 500   3,803.63
DOW   30,983.88
QQQ   316.32
S&P 500   3,803.63
DOW   30,983.88
QQQ   316.32
S&P 500   3,803.63
DOW   30,983.88
QQQ   316.32
S&P 500   3,803.63
DOW   30,983.88
QQQ   316.32
Log in

Co-Diagnostics Stock Forecast, Price & News

+1.14 (+10.82 %)
(As of 01/19/2021 01:45 PM ET)
Today's Range
Now: $11.68
50-Day Range
MA: $10.64
52-Week Range
Now: $11.68
Volume61,544 shs
Average Volume1.28 million shs
Market Capitalization$330.19 million
P/E Ratio14.42
Dividend YieldN/A
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Co-Diagnostics logo


Overall MarketRank

1.68 out of 5 stars

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:CODX



Sales & Book Value

Annual Sales$220,000.00
Book Value$0.10 per share


Net Income$-6,200,000.00


Market Cap$330.19 million
Next Earnings Date3/30/2021 (Estimated)
OptionableNot Optionable
+1.14 (+10.82 %)
(As of 01/19/2021 01:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

How has Co-Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CODX shares have decreased by 11.1% and is now trading at $11.72.
View which stocks have been most impacted by COVID-19

Is Co-Diagnostics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Co-Diagnostics stock.
View analyst ratings for Co-Diagnostics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Co-Diagnostics?

Wall Street analysts have given Co-Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Co-Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, March 30th 2021.
View our earnings forecast for Co-Diagnostics

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) issued its quarterly earnings data on Sunday, November, 15th. The company reported $0.53 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.63 by $0.10. The company had revenue of $21.82 million for the quarter, compared to the consensus estimate of $28 million. Co-Diagnostics had a return on equity of 93.48% and a net margin of 53.81%.
View Co-Diagnostics' earnings history

What guidance has Co-Diagnostics issued on next quarter's earnings?

Co-Diagnostics updated its fourth quarter 2020 IntraDay earnings guidance on Wednesday, January, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $26.184-27.275 million, compared to the consensus revenue estimate of $24.99 million.

What price target have analysts set for CODX?

2 brokerages have issued 1-year price objectives for Co-Diagnostics' shares. Their forecasts range from $20.00 to $30.00. On average, they anticipate Co-Diagnostics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 113.3% from the stock's current price.
View analysts' price targets for Co-Diagnostics
or view Wall Street analyst' top-rated stocks.

Who are some of Co-Diagnostics' key competitors?

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 67, Pay $295k)
  • Dr. Brent C. Satterfield, Co-Founder & Chief Science Officer (Age 43, Pay $237.5k)
  • Mr. Reed L. Benson, CFO & Sec. (Age 72, Pay $215k)
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $11.72.

How big of a company is Co-Diagnostics?

Co-Diagnostics has a market capitalization of $331.32 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 39 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at 801-438-1036 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.